Milk and Reduced Casein-Specific IgE Level

Doses used in studies

Time to effect

Median: 24.3 months · IQR 24.3 months–24.3 months · Range 24.3 months–24.3 months — Reported in 1 of 1 study

Safety in these studies

anaphylaxisIncreased riskSerious adverse event0.01% versus 0.06% in the first year
and anaphylaxis was 0.01% versus 0.06% in the first year
from: Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose.
symptomIncreased risktotal symptom frequency per OIT dose was 0.9% versus 3.8% in the first year, and 0.8% versus 2.0% in the second year (P < .001)
The total symptom frequency per OIT dose was 0.9% versus 3.8% in the first year, and 0.8% versus 2.0% in the second year (P < .001)
from: Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose.

1 of 1 paper

Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose.